A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine protects vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by stimulating the mother’s body’s defences to produce protective antibodies, which are then transferred to the developing baby through the placenta. This mother-derived protection offers newborns with instant defence from the moment of birth, precisely when they are highly susceptible to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence indicating that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst noting that protection remains possible even if administered later in the third trimester.
- Nearly 85 per cent coverage when immunised 4 weeks before birth
- Antibodies from the mother passed through the placenta safeguard newborns from birth
- Protection possible with 2-week gap before early delivery
- Vaccination in the third trimester still provides meaningful protection for infants
Strong evidence from current research
The efficacy of the RSV vaccine administered during pregnancy has been established through a thorough investigation carried out throughout England, reviewing data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that six-month period, providing comprehensive and reliable data of the vaccine’s real-world impact. The study’s findings have been supported by the UK Health Security Agency as showing robust protection for newborns during their most vulnerable early months. The breadth of this investigation offers healthcare professionals and prospective parents with assurance in the vaccine’s proven efficacy across varied populations and settings.
The results reveal a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were admitted to hospital with RSV during the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This stark contrast underscores the vaccine’s critical role in reducing the risk of serious illness in newborns. The drop in hospital admissions exceeding 80 per cent represents a major public health success, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.
Study methodology and scope
The research examined birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection levels and hospital admissions. The sizeable sample and thorough nature of the data collection ensured that findings were statistically robust and indicative of the general population, rather than individual cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to determine the shortest interval needed between vaccination and birth for best possible protection, as well as to determine whether protection continued to be effective with briefer timeframes. The methodology measured practical outcomes rather than experimental conditions, providing real-world data of how the vaccine works when delivered across different clinical contexts and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and its hazards
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.
The infection triggers deep inflammation in the lungs and airways, making it extremely challenging for vulnerable newborns to breathe and feed effectively. Parents commonly see their babies struggling visibly, their chests heaving as they work to get adequate oxygen into their compromised lungs. Whilst the majority of babies recover with supportive care, a small but significant proportion perish from RSV-related complications yearly, making prevention through vaccination a essential public health priority for protecting the youngest and most at-risk people in our communities.
- RSV causes lung inflammation, leading to serious respiratory problems in babies
- Half of all newborns acquire the infection in their first few months of life
- Symptoms span from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK babies need serious hospital treatment for RSV annually
- A small number of infants succumb to RSV complications annually in the UK
Adoption rates and professional guidance
Since the RSV vaccine programme began in 2024, health officials have emphasised the importance of pregnant women getting their jab at the optimal time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that timing is crucial for ensuring newborns benefit from the maximum immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery offers approximately 85% protection, experts encourage women to receive their vaccine as early as possible from 28 weeks of pregnancy forward to enhance the antibodies passed to their babies through the placenta.
The communication from public health bodies remains clear: pregnant women should prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has provided reassurance to expectant mothers that protection remains still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those giving birth ahead of schedule. This flexible approach acknowledges the practical demands of pregnancy whilst ensuring strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional disparities in vaccine uptake
Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Some areas have achieved higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to boost understanding and access to the jab. These regional differences reflect variations in healthcare infrastructure, engagement approaches, and local engagement efforts, though the national data demonstrates consistently strong protection regardless of geographical location.
- NHS trusts rolling out multiple messaging strategies to reach pregnant women
- Regional disparities in immunisation take-up in different parts of England demand focused enhancement
- Community health services adapting programmes to meet community needs and circumstances
Real-world impact and parent viewpoints
The vaccine’s impressive effectiveness translates into real advantages for families throughout the United Kingdom. With over 20,000 babies hospitalised annually due to RSV before the introduction of this preventative solution, the 80% drop in admissions equates to thousands of infants protected against critical disease. Parents no longer face the upsetting situation of watching their newborns gasping for air or difficulty feeding, symptoms that characterise serious RSV disease. The vaccine has substantially transformed the terrain of neonatal respiratory health, providing expectant mothers a active means to protect their youngest infants during those crucial first weeks.
For families like that of Malachi, whose serious RSV infection led to severe brain damage, the vaccine’s availability carries deep personal significance. His mother’s promotion of the jab emphasises the transformative consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story strikes a chord with parents now given protection. The knowledge that such serious complications—hospitalisation, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to expectant mothers during their third trimester, changing what was once an unavoidable seasonal threat into a manageable risk.